Datopotamab deruxtecan

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

EGFRm Advanced Non-Small Cell Lung Cancer

Conditions

EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer

Trial Timeline

— → —

NCT ID

NCT06279728

About Datopotamab deruxtecan

Datopotamab deruxtecan is a pre-clinical stage product being developed by Daiichi Sankyo for EGFRm Advanced Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT06279728. Target conditions include EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06279728	Pre-clinical	Completed	—	—	EGFRm Advanced Non-Small Cell Lung Cancer
NCT06676917	Phase 2	Withdrawn	Jun 1, 2025	Aug 1, 2027	Non-small Cell Lung Cancer
NCT06176261	Phase 2	Recruiting	Jan 8, 2024	Jan 1, 2029	Breast Cancer
NCT05866432	Phase 2	Recruiting	Jul 1, 2023	May 23, 2026	Breast Cancer Stage IV

Competing Products

3 competing products in EGFRm Advanced Non-Small Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
Osimertinib-based adaptive treatment + Osimertinib 80 MG	AstraZeneca	Phase 2	42
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel + Pemetrexed	Roche	Phase 2	35
PF-06459988	Pfizer	Phase 2	27